Skip to main content
Download PDF

Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Journal of Hematology & Oncology volume 17, Article number: 98 (2024) Cite this article

The Original Article was published on 19 September 2024

Correction: Journal of Hematology & Oncology (2024) 17:86

https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13045-024-01606-w

The authors’ names in the authorship of the original article were mistakenly inverted and have since been amended.

Author information

Authors and Affiliations

  1. CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France

    Marion Alcantara

  2. Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France

    Marion Alcantara & Carole Soussain

  3. Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France

    Marion Chevrier

  4. Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France

    Fabrice Jardin

  5. Service d’Hématologie, Institut Bergonié, Bordeaux, France

    Anna Schmitt

  6. Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

    Caroline Houillier & Khê Hoang-Xuan

  7. Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France

    Lucie Oberic

  8. AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France

    Olivier Chinot

  9. Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France

    Franck Morschhauser

  10. Service d’Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France

    Frédéric Peyrade

  11. Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France

    Roch Houot

  12. Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France

    Hervé Ghesquieres

  13. Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France

    Carole Soussain

Authors
  1. Marion Alcantara
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Marion Chevrier
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Fabrice Jardin
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Anna Schmitt
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Caroline Houillier
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Lucie Oberic
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Olivier Chinot
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Franck Morschhauser
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Frédéric Peyrade
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Roch Houot
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. Khê Hoang-Xuan
    View author publications

    You can also search for this author inPubMed Google Scholar

  12. Hervé Ghesquieres
    View author publications

    You can also search for this author inPubMed Google Scholar

  13. Carole Soussain
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Carole Soussain.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13045-024-01606-w.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alcantara, M., Chevrier, M., Jardin, F. et al. Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. J Hematol Oncol 17, 98 (2024). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13045-024-01620-y

Download citation

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13045-024-01620-y

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us